News

Robbins discusses the exciting future of true designer drugs in the works for migraine prevention as well as the challenges that remain in the space.

Seasickness can be difficult to manage once symptoms begin. However, there are some physiological characteristics to help patients manage symptoms.

Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.

For those at-risk for Parkinson disease, reducing systemic inflammation could decrease the incidence of the movement disorder.

Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.

The results indicated that 38% of patients responded to the device whereas 11% of patients responded when using the sham device.

The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.

This is the first study to utilize artificial intelligence for detecting a wide range of acute neurologic events, demonstrating a direct clinical application.

The nonselective ß-blocker proved efficacious in comparison with placebo in a pilot trial.

Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.

Darin Okuda, MD, provides insight into the nuances that come with the treatment of MS with disease-modifying therapies.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.

Could GlaxoSmithKline and 23andMe use genetic data to create landscape-altering therapies for hard-to-treat conditions?

DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.

Can better collaboration between industry and clinicians solve the challenges that plague the Alzheimer community?

Nabilone significantly improved agitation, neuropsychiatric symptoms, cognition and nutrition in patients with moderate-to-severe Alzheimer disease.

Neurology Times invited David E. Olson, PhD to discuss a new study that sheds light on the role of psychedelics in promoting neuritogenesis, spinogenesis, and synaptogenesis.

The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.

The findings suggest that intensive lowering of blood pressure may reduce the risk of mild cognitive impairment and the combined risk of mild cognitive impairment and dementia, but not dementia alone.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health discussed his thoughts about patients with mild dementia and prodromal Alzheimer disease.

The increased risk of hemorrhage was not revealed in 5-mg and 10-mg doses, implying a dose-dependent effect for rivaroxaban.

Paramedics were called to a campus party after a 911 call was placed with a report that a 19-year-old male suddenly “passed out.”

Data back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.

Midazolam is expected to receive a decision from the FDA in early 2019. If approved, it would become the first new medication for this indication in more than 15 years.

The Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program discussed the landscape of care in Alzheimer symptom management.

Hampel looks to the future of the Alzheimer space and sees promise, especially since there’s transfertilization from other advanced science fields in medicine like oncology, diabetes research and rheumatology.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the difficulties of treating sleepiness and what solriamfetol brings to the table.

The vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke about the upcoming TANGO II trial in Alzheimer disease.